Issue Date: May 10, 2010
Merck Acquires Ariad Cancer Drug
Merck & Co. has acquired development and worldwide commercialization rights for ridaforolimus, an Ariad Pharmaceuticals drug now in Phase III trials as a treatment for metastatic soft-tissue and bone cancers. Merck will pay Ariad $50 million up front and up to $514 million in milestone payments. The two firms started collaborating on the drug, a small-molecule inhibitor of the cell proliferation protein mTOR, in July 2007. Ariad says the deal will allow it to devote resources to two other cancer therapies in its pipeline.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society